Online citations, reference lists, and bibliographies.
← Back to Search

Immunohistochemical Detection Of DNA Topoisomerase IIalpha, P-glycoprotein And Multidrug Resistance Protein (MRP) In Small-cell And Non-small-cell Lung Cancer.

J. Kreisholt, M. Sørensen, P. B. Jensen, B. Nielsen, C. Andersen, M. Sehested
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) differ significantly in their clinical response to topoisomerase IIalpha (topo-IIalpha)-directed drugs, such as etoposide and teniposide, as NSCLC is virtually insensitive to single-agent therapy, while SCLC responds in two-thirds of cases. Preclinical studies have indicated that resistance to topo-IIalpha drugs depends on topo-IIalpha content and/or activity, the altered-topo-II multidrug resistance phenotype (at-MDR) and/or one of two different drug efflux pumps, P-glycoprotein (P-gp) and the multidrug resistance protein (MRP). Immunohistochemical analysis on paraffin-embedded tissue from 27 cases of untreated NSCLC and 29 cases of untreated SCLC (of which additional tumour biopsies after treatment with topo-IIalpha-directed drugs were available in ten cases) yielded the following results: NSCLC had significantly less topo-IIalpha than SCLC (P < 0.0001), as only 5 out of 27 NSCLC cases had > 5% positive cells compared with 28 out of 29 SCLC, and 0 out of 27 NSCLC had > 25% positive cells compared with 26 out of 29 SCLC. P-gp was detected in > 5% of cells in only 3 out of 27 NSCLC and in 6 out of 29 SCLC, and MRP in 5 out of 27 of NSCLC and 9 out of 29 SCLC. After treatment of patients with SCLC with either etoposide or teniposide, which are topo-IIalpha-directed drugs, there was an increase in MRP (P < 0.1) and P-gp (P < 0.05) positivity, while topo-IIalpha decreased (P < 0.05). In conclusion, the major difference between untreated NSCLC and SCLC was in topo-IIalpha content. In the small series of ten patients treated for SCLC, all three MDR phenotypes appeared to increase.
This paper references
British Journal of Cancer Cancer Research Campaign
Wt Beck (1473)
Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.
Y. Pommier (1986)
10.1021/BI00424A026
Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
M. Danks (1988)
10.1002/IJC.2910430229
Immunohistochemical detection of P‐glycoprotein in human tumor cells with a low degree of drug resistance
H. J. Broxterman (1989)
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
S. de Jong (1990)
10.1093/AJCP/94.3.368B
Expression of a multidrug resistance gene.
S. González (1990)
Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
C. Webb (1991)
10.1038/bjc.1991.384
Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers.
M. Volm (1991)
Attenuated topisomerase II content
CD Webb (1991)
10.1126/SCIENCE.1360704
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.
S. Cole (1992)
Expression of the multidrugresistance-associated protein (MRP) gene in human colorectal, gastric and nonsmall-cell lung carcinomas
SPC Cole (1992)
Clinical correlates of MDR1 (P-glycoprotein) in ovarian and small-cell lung carcinomas
Ta Holzmayer (1992)
Overexpression of a transporter gene
SPC Cole (1992)
Clinical correlates of MDR 1 ( P - glycoprotein ) in ovarian and small - cell lung carcinomas
Jarvinen TAH (1992)
10.1016/0163-7258(93)90011-2
Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.
P. Borst (1993)
10.11501/3072838
MDR1 gene expression and treatment outcome in small cell lung cancer : MDR1 gene expression as an independent prognostic factor
田端 雅弘 (1993)
A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
J. Nitiss (1993)
10.1016/0169-5002(94)93885-7
MDR1 gene expression and treatment outcome in small cell lung cancer: MDR1 gene expression as an independent prognostic factor.
M. Tabata (1993)
10.18926/AMO/31590
Immunohistochemical detection of P-glycoprotein and carcinoembryonic antigen in small cell lung cancer: with reference to predictability of response to chemotherapy.
Y. Segawa (1993)
Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1.
H. Kreipe (1993)
Prognostic significance of a formalinresistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody KiS 1
Mirski SEL (1993)
Immunohistochemical detection of P-glycoprotein
Y Segawa (1993)
Temperature sensitive topoisomeraseI 1 allele confers temperature dependent drug resistance on amsacrine and etoposidea genetic system for determining the targets of topoisomeraseII inhibitors
K Nooter (1993)
10.1146/ANNUREV.PA.34.040194.001203
DNA topoisomerases: essential enzymes and lethal targets.
A. Y. Chen (1994)
10.1002/IJC.2910590509
Parallel assessment of glutathione‐based detoxifying enzymes, O6‐alkylguanine‐dna alkyltransferase and P‐glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer
Aurelia E. Oberli‐Schrämml (1994)
10.1111/j.1349-7006.1994.tb02392.x
Expression of the Multidrug Resistance Gene (MDR1) in Non‐small Cell Lung Cancer
Y. Abe (1994)
Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies.
M. Flens (1994)
10.1016/0959-8049(94)00290-L
Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation.
G. Thomas (1994)
Role of mdrl and p53 expression in the chemoresistance of lung carcinomas
M Peoch (1994)
Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.
I. Brock (1995)
10.1038/bjc.1995.372
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.
Eiichiro Ota (1995)
10.1002/IJC.2910640507
Preferential expression of the multidurg‐resistance‐associated protein (MRP) in adenocarcinoma of the lung
I. Sugawara (1995)
Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
W. Harker (1995)
Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.
F. Boege (1995)
Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line.
S. Mirski (1995)
Adenocarcinoma of the lung.
A. R. Patel (1995)
10.1136/jcp.48.2.147
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
P. Hellemans (1995)
Sequential co-expression of the multidrug resistance genes, MRP and mdrl and their products in VP-16 (etoposide) selected H69 small cell lung cancer cells
I Brock (1995)
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
W. Beck (1996)
10.3892/IJO.8.3.537
Comparison of the mRNA expression of factors related to drug resistance in lung tumors and adjacent normal tissue.
Gerd Stammler (1996)
10.1136/thx.51.5.526
Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.
T. Beer (1996)
Multidrug resistance-associated protein (MRP) gene expression in human lung cancer.
F. Narasaki (1996)
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.
T. Järvinen (1996)
10.1002/(SICI)1097-0142(19960815)78:4<729::AID-CNCR6>3.0.CO;2-9
Comparison of DNA topoisomerase IIα expression in small cell and nonsmall cell carcinoma of the lung: In search of a mechanism of chemotherapeutic response
D. Guinee (1996)
10.3109/02841869609109915
Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity.
K. Yamazaki (1996)
10.1016/0959-8049(96)00045-7
How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein.
H. Broxterman (1996)
10.1002/(SICI)1097-0215(19960611)66:6<760::AID-IJC9>3.0.CO;2-Y
MRP is frequently expressed in human lung‐cancer cell lines, in non‐small‐cell lung cancer and in normal lung
G. Giaccone (1996)
Expression of the multidrug resistanceassociated protein ( MRP ) gene in primary non - small - cell lung cancer
AE Oberli-Schrammli (1996)
essential enzymes and lethal targets
Y Chuman (1996)
Expression of the multidrug resistance-associated protein (MRP) gene in primary nonsmall-cell lung cancer
K Nooter (1996)
Expression of the multidrugresistanceassociated protein ( MRP ) gene in human colorectal , gastric and non - small - cell lung carcinomas
Cole SPC (1996)
Expression of the multidrugresistance-associated protein (MRP) gene in human colorectal, gastric and nonsmall-cell lung carcinomas
Y Chuman (1996)
Response of cellular DNA topoisomerases to induction of full - length E 2 FI / DP1 transcription factor ( abstract )
TA Holzmayer (1997)
Response of cellular DNA topoisomerases to induction
M Sehested (1997)
Altemative splicing leading to a deletion of bp 4468-76 coding for Lys-Ser-Lys in topoisomerase II a (Topo II) in small cell lung cancer H69/VP cells resistant
PB Jensen (1997)
Response of cellular DNA topoisomerases to induction of full-length E2F-I/DP-1 transcription factor (abstract)
K Hofland (1997)
Cancer Research Campaign British Joural of Cancer
(1998)
10.1097/00063198-200007000-00022
Management of small cell cancer of the lung.
A. Adjei (2000)



This paper is referenced by
10.1111/1759-7714.13289
Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
R. Sakurai (2020)
10.1016/j.jff.2019.103553
EGCG maintained Nrf2-mediated redox homeostasis and minimized etoposide resistance in lung cancer cells
S. Datta (2019)
In vitro evaluation of the efficacy of selected medicinal plant extracts against multidrug resistant cancer cells
Roan A. Swanepoel (2017)
10.1007/978-3-319-24223-1_10
Chemotherapy Resistance in Lung Cancer.
E. Kim (2016)
Multidrug resistance-associated protein 2 (MRP2) and oxaliplatin transport
Khine Myint (2015)
Investigation of the Function and Regulation of ABC Transporters
B. G. Akkaya (2014)
10.3103/S0027131412030054
Quantitative immunofluorescence estimation of Pgp expression in human solid tumors by flow cytometry
T. Bogush (2012)
10.3978/j.issn.2072-1439.2012.08.04
The association of topoisomerase 2α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients.
Hulya Çelenk Erguden (2012)
10.1002/jgm.2630
Single agent‐ and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells
S. R. Michaelsen (2012)
10.1007/978-1-60761-524-8_15
Lung Cancer Resistance to Chemotherapy
D. J. Stewart (2010)
10.1016/j.critrevonc.2009.11.006
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
David J Stewart (2010)
10.1109/FBIE.2009.5405779
Relationship between methylation status of multi-drug resistance protein (MRP) and multi-drug resistance in lung cancer cell lines
H. Li (2009)
10.1002/cncr.23981
Placental isoform glutathione S‐transferase and P‐glycoprotein expression in advanced nonsmall cell lung cancer
George S Vlachogeorgos (2008)
10.1016/j.lungcan.2008.03.010
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
C. Hsu (2008)
10.1007/S11670-007-0277-0
Relationship between methylation status of multi-drug resistance protein(MRP) and multi-drug resistance in lung cancer cell lines
R. Liu (2007)
MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer.
S. Roy (2007)
10.1080/09553000701570204
Extracellular matrix regulation of drug resistance in small-cell lung cancer
P. Hodkinson (2007)
10.1007/978-1-59745-035-5_18
Resistance To Taxanes
L. Greenberger (2006)
10.1007/s00424-006-0160-8
Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1)
Éva Bakos (2006)
10.1152/PHYSREV.00035.2005
Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.
R. G. Deeley (2006)
10.1016/S0304-4858(06)74552-8
Expresión de Proteínas Relacionadas con Resistencia a Múltiples Drogas (MDR-Proteínas) en tumores sólidos
A. Paredes-Lario (2006)
10.1016/S0009-739X(06)70855-7
Expresión de proteínas relacionadas con resistencia a múltiples fármacos (MDR-proteínas) en tumores sólidos
Alfredo Paredes (2006)
Comparison of Chemotherapy Response with P-Glycoprotein, Multidrug Resistance-Related Protein-1, and Lung Resistance-Related Protein Expression in Untreated Small Cell Lung Cancer
P. Tung (2005)
10.1007/1-4020-3414-8_18
Integrin-Mediated Resistance to Chemotherapy-Induced Apoptosis in Cancer Cells
R. Rintoul (2005)
10.1007/s00408-004-2532-1
Comparison of Chemotherapy Response with P-Glycoprotein, Multidrug Resistance-Related Protein-1, and Lung Resistance-Related Protein Expression in Untreated Small Cell Lung Cancer
J. Yeh (2004)
10.1159/000073845
Technetium-99m Tetrofosmin SPECT Predicts Chemotherapy Response in Small Cell Lung Cancer
J. Yeh (2003)
10.1124/pr.55.1.4
Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
R. Danesi (2003)
10.1016/B978-012352551-2/50020-2
CHAPTER 19 – MULTIDRUG RESISTANCE PROTEIN 1 (ABCC1)
R. G. Deeley (2003)
10.1016/S0969-8051(03)00058-1
To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression.
Tsung-Huai Kuo (2003)
10.1385/MO:20:3:247
Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with p-glycoprotein expression in patients with untreted small cell lung cancer
Sheng-Pin Changlai (2003)
10.1159/000068411
Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression
J. Yeh (2003)
10.1016/B0-12-227555-1/00153-2
Multidrug Resistance II: MRP and Related Proteins
S. Cole (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar